<DOC>
	<DOCNO>NCT02422927</DOCNO>
	<brief_summary>The investigator test nutraceutical combination red yeast rice , berberine policosanol ( NC ) significantly modify inflammation , lipid profile marker endothelial injury ( endothelial microparticles ) subject elevate level high-sensitivity C-reactive protein ( hsCRP ) .</brief_summary>
	<brief_title>Nutraceutical Combination Patients With Low-grade Systemic Inflammation</brief_title>
	<detailed_description>Will include study 100 subject suboptimal LDL cholesterol level ( LDL 100-160 mg / dL ) hsCRP level &gt; 2 mg / L , divide two group equal number , match sex age , randomize receive nutraceutical combination contain red yeast 200 mg , berberine 500 mg policosanol 10 mg ( NC ) combination low-cholesterol diet ( &lt; 200 mg / day ) low-cholesterol diet ( Standard Care - SOC ) . All subject time inclusion study protocol prescribe SOC period 30 day ( Lipid Stabilization Period : LSP ) ; After 30 day LSP perform randomization two intervention arm : NC + SOC SOC .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>LDL cholesterol &lt; 160 mg/dl ( 4,14 mmol/l ) ; hsCRP &gt; 2 mg/L ; triglyceride &gt; 500 mg/dL ( 5.6 mmol/L ) ; current previous treatment lipidlowering drug drug suppose modify vascular damage and/or repair ( antiplatelet , antihypertensive antioxidant drug ) ; current previous treatment hormone replacement therapy menopause vasomotor symptom ; evidence liver dysfunction alanineaminotransferase ( ALT ) level twice upper normal limit ; creatinkinase ( CK ) level thrice upper normal limit history clinical evidence previous current cardiovascular disease ; presence strong cardiovascular risk factor : serum creatinine level &gt; 2 mg/dL , diabetes mellitus , uncontrolled systemic arterial hypertension ( systolic blood pressure &gt; 190 mg/dL diastolic blood pressure &gt; 100 mg/dL ) ; history cancer former 5 year recruitment ; adequately treat hypothyroidism ( TSH level &gt; 1,5 time upper normal limit ) ; history malignancy previous 5 year screen ; adequately treat hypothyroidism ( TSH level &gt; 1,5 time upper normal limit ) ; previous current alcohol drug abuse ; history clinical evidence chronic inflammatory disease severe arthritis , systemic lupus erythematosus chronic inflammatory bowel disease ; current previous use immunosuppressant agent long term glucocorticoid history clinical evidence severe concomitant disease may compromise subject 's safety possibility carry study .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>C-Reactive Protein</keyword>
	<keyword>Endothelial Microparticles</keyword>
	<keyword>Endothelium</keyword>
	<keyword>Nutraceutical</keyword>
	<keyword>Cholesterol</keyword>
</DOC>